CurrentEmblemHealthPolicy AHS-M2067

Therapeutic Drug Monitoring for 5‑Fluorouracil (5‑FU)

Customize your policy alerts

Sign up for EmblemHealth Policy AHS-M2067 alerts

Get alerted when Policy AHS-M2067 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This reimbursement policy governs coverage and limitations for therapeutic drug monitoring (TDM) of 5‑fluorouracil (5‑FU) for individuals receiving 5‑FU chemotherapy under EmblemHealth plans, including which specific tests meet or do not meet coverage criteria.

Policy Summary

PayerEmblemHealth

PolicyTherapeutic Drug Monitoring for 5‑Fluorouracil (5‑FU)

Policy CodePolicy AHS-M2067

Change TypeRevision (formatting/reorganization)

Effective DateJun 13, 2025

Next Review DateN/A

Key ActionTherapeutic drug monitoring (TDM) for individuals receiving 5‑FU chemotherapy meets coverage criteria; uracil breath tests and dihydrouracil/uracil ratio testing do not meet coverage criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentEmblemHealthPolicy AHS-M2067

Therapeutic Drug Monitoring for 5‑Fluorouracil (5‑FU)

Customize your policy alerts

Sign up for EmblemHealth Policy AHS-M2067 alerts

Get alerted when Policy AHS-M2067 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerEmblemHealth

PolicyTherapeutic Drug Monitoring for 5‑Fluorouracil (5‑FU)

Policy CodePolicy AHS-M2067

Change TypeRevision (formatting/reorganization)

Effective DateJun 13, 2025

Next Review DateN/A

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

20-30recommended 5-FU AUC target range

654meta-analysis pooled sample

71%% patients >75 yrs dose adj.

153randomized trial size

S3722,80299,82542,83789applicable procedure codes

Coverage Criteria for 5‑Fluorouracil Therapeutic Drug Monitoring

Coverage determinations for 5-FU TDM

Application of coverage criteria depends on the individual's benefit coverage. Medicare/Medicaid specifications are in the Applicable State and Federal Regulations section of this policy document.

Coverage determinations for therapeutic drug monitoring (TDM) of 5‑fluorouracil (5‑FU) are applied based on the individual's benefit coverage; see Applicable State and Federal Regulations for Medicare/Medicaid specifications.

Covered

For individuals undergoing 5‑fluorouracil chemotherapy, therapeutic drug monitoring (TDM) to aid in managing dose adjustment meets coverage criteria.

Not covered

Uracil breath tests do NOT meet coverage criteria due to insufficient published scientific literature confirming clinical benefit.
Dihydrouracil/uracil ratio testing of plasma, serum, or urine samples does NOT meet coverage criteria due to insufficient published scientific literature confirming clinical benefit.

Coverage‑relevant recommendations and evidence (partial)

Guidance and recommendations relevant to when TDM or DPD testing may be used:

IATDMCT: AUC is the accepted and clinically relevant metric for assessing systemic 5‑FU exposure; IATDMCT strongly recommends TDM for management of 5‑FU therapy in colorectal or head‑and‑neck cancer to reduce variability and toxicity and improve clinical activity. Note: IATDMCT does not recommend the uracil breath test.

Guideline (Amstutz et al., RNPGx/GPCO): Pharmacokinetically‑guided (AUC) dosing increases the proportion of patients with 5‑FU exposure within the therapeutic target range and reduces some 5‑FU related adverse effects; follow‑up TDM is recommended to avoid underdosing after genotype‑based dose reductions.

DPYD/DPD guidance (RNPGx/GPCO): EMA recommends DPD testing (genotyping or uracilemia) before fluoropyrimidine chemotherapy; DPYD genotype‑guided dose reduction is clinically validated (with limitations by ancestry); TDM is recommended in DPD‑deficient patients.

Dose management recommendations for DPYD phenotypes

For DPYD poor metabolizers: if alternative agents are not suitable, administer 5‑FU at a strongly reduced dose with early therapeutic drug monitoring.

Coverage and Reimbursement

Reimbursement policy section exists though specific coverage criteria, billing codes, and detailed authorization requirements are not present in these pages.

A reimbursement policy for Therapeutic Drug Monitoring for 5‑Fluorouracil (Lab Benefit Program) is established (Reimbursement Policy AHS‑M2067).

Procedure codes and billing guidance are referenced elsewhere in the policy (see coding section) for AUC dose optimization and related laboratory quantitation methods; specific authorization or detailed reimbursement rules are not included in this excerpt.

Coding and Procedure Codes

Coding guidance and editsmixed

No codes listed

Applicable procedure codesmixed

S3722	Dose optimization by area under the curve (AUC) analysis, for infusional 5‑fluorouracil
80299	Quantitation of therapeutic drug, not elsewhere specified
82542	Column chromatography, includes mass spectrometry, if performed
83789	Mass spectrometry and tandem mass spectrometry, non‑drug analyte(s), qualitative or quantitative

Not specified in this sectionmixed

No codes listed

AUC target range

Recommended AUC target range20-30 mg·h/L

Unit of measuremg·h/L (milligram‑hours per liter)

Clinical contextTarget applies to continuous intravenous infusional 5‑FU dosing to guide therapeutic drug monitoring

Coding note

Coding specificationNot specified in this policy excerpt; coding note placeholder for local billing guidance

ActionRefer to Applicable CPT/HCPCS procedure codes section for billable assays and services

Provider Actions and Billing Notes

Prior Authorization

Coverage: 5‑FU TDM meets criteria; certain tests not covered

For individuals undergoing 5-fluorouracil chemotherapy, therapeutic drug monitoring (TDM) to aid in managing dose adjustment meets coverage criteria; uracil breath tests and dihydrouracil/uracil ratio testing do not meet coverage criteria.

Billing Rule

Procedure codes for 5‑FU TDM

Use the listed procedure codes when billing for 5‑FU TDM AUC analysis and laboratory quantitation/mass spectrometry services: S3722, 80299, 82542, 83789.

S3722 — Dose optimization by area under the curve (AUC) analysis, for infusional 5‑fluorouracil
80299 — Quantitation of therapeutic drug, not elsewhere specified

Definitions and Key Terms

Selected terms

5-FU5‑fluorouracil

AUCArea‑under‑curve (systemic exposure metric)

BSABody surface area

DPDDihydropyrimidine dehydrogenase

TDMTherapeutic drug monitoring

AUC

DefinitionArea‑under‑curve (AUC) — a systemic exposure metric used to guide 5‑FU dosing

Background, Evidence, and References

This policy references guideline and position statements that inform when therapeutic drug monitoring (TDM) or DPD testing may be appropriate for managing 5‑fluorouracil (5‑FU) therapy. The IATDMCT strongly recommends use of TDM for management of 5‑FU in colorectal and head‑and‑neck cancer, noting that AUC is the accepted and clinically relevant metric and that TDM can reduce variability and toxicity while improving clinical activity. The IATDMCT also states the uracil breath test is not recommended for dose determination. (IATDMCT guidance.)

Guidance from pharmacogenetics and oncology groups recommends integrating DPD (DPYD) assessment with therapeutic monitoring: RNPGx/GPCO-UNICANCER and related summaries note that European regulators (EMA) recommend DPD testing prior to fluoropyrimidine therapy, support genotype‑guided dose reductions, and recommend TDM in DPD‑deficient patients. Similarly, pharmacokinetic guidance advises that PK‑guided dosing increases the proportion of patients with 5‑FU AUC within the therapeutic range and reduces 5‑FU‑related adverse effects; follow‑up TDM is recommended after genotype‑based dose reductions to avoid underdosing.

Operationally, these external recommendations inform the policy’s coverage stance: TDM using validated AUC‑based assays is supported by professional guidance and evidence summaries for dose optimization in select 5‑FU regimens, whereas uracil breath testing is discouraged and DPD testing has a distinct role in genotype/phenotype‑guided initial dosing and identification of deficient patients who may require both dose reduction and early TDM.

Therapeutic drug monitoring (TDM) for 5‑fluorouracil (5‑FU) is grounded in the agent’s narrow therapeutic index and the relationship between systemic exposure and both efficacy and toxicity. The policy notes that continuous infusion 5‑FU has been the focus of PK‑guided, AUC‑based dosing strategies aimed at keeping exposure within a target range (recommended AUC target 20–30 mg·h/L) to reduce toxicity and improve clinical outcomes.

A substantive evidence base and multiple guideline documents support AUC‑guided TDM. Systematic reviews, randomized trials, and observational studies (including multicenter and population pharmacology reports) have demonstrated that PK‑guided dosing increases the proportion of patients achieving target AUC and can reduce 5‑FU‑related adverse events; several professional groups (IATDMCT, STP‑PT/GPCO, and RNPGx summaries) explicitly endorse TDM in selected clinical scenarios.

Policy Revision History

2025-02revisionLatest

Policy reformatted and reorganized; transferred to new template with new Reimbursement Policy Number.

Policy Summary

PayerEmblemHealth

PolicyTherapeutic Drug Monitoring for 5‑Fluorouracil (5‑FU)

Policy CodePolicy AHS-M2067

Change TypeRevision (formatting/reorganization)

Effective DateJun 13, 2025

Next Review DateN/A

SourceLink

On This Page

For DPYD intermediate metabolizers: reduce starting dose based on activity score followed by titration based on toxicity or therapeutic drug monitoring (if available).

Next stepConfirm code assignment with billing department or payor-specific guidance

82542 — Column chromatography, includes mass spectrometry, if performed

83789 — Mass spectrometry and tandem mass spectrometry, non‑drug analyte(s), qualitative or quantitative

Note

Reimbursement policy present (Lab Benefit Program)

The policy includes a Reimbursement Policy section for Therapeutic Drug Monitoring for 5‑Fluorouracil within the Lab Benefit Program (LBM).

IATDMCT identifies AUC as the accepted and clinically relevant metric correlating with 5‑FU activity and toxicity

Target range referencePolicy recommends aiming for AUC 20–30 mg·h/L for continuous infusional 5‑FU

DPD testing / DPYD genotyping / uracilemia

DefinitionDPD testing includes DPYD genotyping and uracilemia phenotyping to identify dihydropyrimidine dehydrogenase deficiency that affects 5‑FU metabolism

Clinical roleUsed to detect patients at risk for increased 5‑FU exposure/toxicity and to guide dose reductions or use of TDM

Guideline noteEMA and RNPGx/GPCO recommend DPD testing before fluoropyrimidine chemotherapy; genotyping‑guided dose reductions are clinically validated

Therapeutic Drug Monitoring (TDM) for 5‑Fluorouracil

DefinitionTherapeutic Drug Monitoring (TDM) — the clinical practice of measuring specific drug concentrations at designated intervals to optimize individual dosing regimens

PurposeTDM for 5‑FU is used to adjust doses to achieve target AUC, reduce toxicity, and improve efficacy compared with BSA‑based dosing

Guideline supportIATDMCT and other guideline bodies strongly recommend TDM for management of 5‑FU in certain cancers and in DPD‑deficient patients

DPD (DPYD) testing—by genotyping or uracilemia phenotyping—serves a complementary role: regulatory summaries (EMA) and expert groups recommend DPD screening before fluoropyrimidine therapy, and genotype‑guided dose reductions are supported by clinical validation. For patients identified as DPD‑deficient, guidelines recommend significant dose reduction and early therapeutic monitoring, and multiple sources recommend TDM specifically for DPD‑deficient patients to guide safe re‑introduction or dose adjustment of 5‑FU.

Not all assays or approaches have equal support. The IATDMCT explicitly does not recommend the uracil breath test for dose determination. The policy emphasizes use of validated analytic methods (for example, LC‑MS/MS or other quantitative assays cited in the literature and reviews) and alignment with the cited guideline recommendations when applying TDM in clinical practice.